684 related articles for article (PubMed ID: 22851554)
1. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.
Burnett AK; Russell NH; Hills RK; Kell J; Freeman S; Kjeldsen L; Hunter AE; Yin J; Craddock CF; Dufva IH; Wheatley K; Milligan D
J Clin Oncol; 2012 Nov; 30(32):3924-31. PubMed ID: 22851554
[TBL] [Abstract][Full Text] [Related]
2. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.
Burnett AK; Hills RK; Milligan D; Kjeldsen L; Kell J; Russell NH; Yin JA; Hunter A; Goldstone AH; Wheatley K
J Clin Oncol; 2011 Feb; 29(4):369-77. PubMed ID: 21172891
[TBL] [Abstract][Full Text] [Related]
3. A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.
Burnett AK; Russell NH; Hills RK; Kell J; Nielsen OJ; Dennis M; Cahalin P; Pocock C; Ali S; Burns S; Freeman S; Milligan D; Clark RE
Leukemia; 2017 Feb; 31(2):310-317. PubMed ID: 27624670
[TBL] [Abstract][Full Text] [Related]
4. Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.
Malfuson JV; Konopacki J; Thepenier C; Eddou H; Foissaud V; de Revel T
Ann Hematol; 2012 Dec; 91(12):1871-7. PubMed ID: 22820971
[TBL] [Abstract][Full Text] [Related]
5. Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse.
Pilorge S; Rigaudeau S; Rabian F; Sarkozy C; Taksin AL; Farhat H; Merabet F; Ghez S; Raggueneau V; Terré C; Garcia I; Renneville A; Preudhomme C; Castaigne S; Rousselot P
Am J Hematol; 2014 Apr; 89(4):399-403. PubMed ID: 24375467
[TBL] [Abstract][Full Text] [Related]
6. Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17).
Amadori S; Suciu S; Stasi R; Salih HR; Selleslag D; Muus P; De Fabritiis P; Venditti A; Ho AD; Lübbert M; Thomas X; Latagliata R; Halkes CJ; Falzetti F; Magro D; Guimaraes JE; Berneman Z; Specchia G; Karrasch M; Fazi P; Vignetti M; Willemze R; de Witte T; Marie JP
J Clin Oncol; 2013 Dec; 31(35):4424-30. PubMed ID: 24127442
[TBL] [Abstract][Full Text] [Related]
7. Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients.
Brunnberg U; Mohr M; Noppeney R; Dürk HA; Sauerland MC; Müller-Tidow C; Krug U; Koschmieder S; Kessler T; Mesters RM; Schulz C; Kosch M; Büchner T; Ehninger G; Dührsen U; Serve H; Berdel WE
Ann Oncol; 2012 Apr; 23(4):990-6. PubMed ID: 21810729
[TBL] [Abstract][Full Text] [Related]
8. High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk.
Tavor S; Rahamim E; Sarid N; Rozovski U; Gibstein L; Aviv F; Kirsner I; Naparstek E
Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):438-43. PubMed ID: 23017331
[TBL] [Abstract][Full Text] [Related]
9. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
Candoni A; Martinelli G; Toffoletti E; Chiarvesio A; Tiribelli M; Malagola M; Piccaluga PP; Michelutti A; Simeone E; Damiani D; Russo D; Fanin R
Leuk Res; 2008 Dec; 32(12):1800-8. PubMed ID: 18621416
[TBL] [Abstract][Full Text] [Related]
10. Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).
de Witte T; Suciu S; Meert L; Halkes C; Selleslag D; Bron D; Amadori S; Willemze R; Muus P; Baron F
Ann Hematol; 2015 Dec; 94(12):1981-9. PubMed ID: 26410352
[TBL] [Abstract][Full Text] [Related]
11. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.
Hills RK; Castaigne S; Appelbaum FR; Delaunay J; Petersdorf S; Othus M; Estey EH; Dombret H; Chevret S; Ifrah N; Cahn JY; Récher C; Chilton L; Moorman AV; Burnett AK
Lancet Oncol; 2014 Aug; 15(9):986-96. PubMed ID: 25008258
[TBL] [Abstract][Full Text] [Related]
12. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial.
Faderl S; Wetzler M; Rizzieri D; Schiller G; Jagasia M; Stuart R; Ganguly S; Avigan D; Craig M; Collins R; Maris M; Kovacsovics T; Goldberg S; Seiter K; Hari P; Greiner J; Vey N; Recher C; Ravandi F; Wang ES; Vasconcelles M; Huebner D; Kantarjian HM
J Clin Oncol; 2012 Jul; 30(20):2492-9. PubMed ID: 22585697
[TBL] [Abstract][Full Text] [Related]
13. Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial).
Willemze R; Suciu S; Muus P; Halkes CJ; Meloni G; Meert L; Karrasch M; Rapion J; Vignetti M; Amadori S; de Witte T; Marie JP
Ann Hematol; 2014 Jun; 93(6):965-75. PubMed ID: 24682421
[TBL] [Abstract][Full Text] [Related]
14. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.
Gamis AS; Alonzo TA; Meshinchi S; Sung L; Gerbing RB; Raimondi SC; Hirsch BA; Kahwash SB; Heerema-McKenney A; Winter L; Glick K; Davies SM; Byron P; Smith FO; Aplenc R
J Clin Oncol; 2014 Sep; 32(27):3021-32. PubMed ID: 25092781
[TBL] [Abstract][Full Text] [Related]
15. Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials.
Li X; Xu SN; Qin DB; Tan Y; Gong Q; Chen JP
Ann Oncol; 2014 Feb; 25(2):455-61. PubMed ID: 24478322
[TBL] [Abstract][Full Text] [Related]
16. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
Jabbour E; Garcia-Manero G; Cortes J; Ravandi F; Plunkett W; Gandhi V; Faderl S; O'Brien S; Borthakur G; Kadia T; Burger J; Konopleva M; Brandt M; Huang X; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):244-51. PubMed ID: 22534616
[TBL] [Abstract][Full Text] [Related]
17. G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.
Becker PS; Medeiros BC; Stein AS; Othus M; Appelbaum FR; Forman SJ; Scott BL; Hendrie PC; Gardner KM; Pagel JM; Walter RB; Parks C; Wood BL; Abkowitz JL; Estey EH
Am J Hematol; 2015 Apr; 90(4):295-300. PubMed ID: 25545153
[TBL] [Abstract][Full Text] [Related]
18. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.
Petersdorf SH; Kopecky KJ; Slovak M; Willman C; Nevill T; Brandwein J; Larson RA; Erba HP; Stiff PJ; Stuart RK; Walter RB; Tallman MS; Stenke L; Appelbaum FR
Blood; 2013 Jun; 121(24):4854-60. PubMed ID: 23591789
[TBL] [Abstract][Full Text] [Related]
19. Gemtuzumab ozogamicin in combination with attenuated doses of standard induction chemotherapy can successfully induce complete remission without increasing toxicity in patients with acute myeloid leukemia aged 55 or older.
Eom KS; Kim HJ; Min WS; Lee S; Min CK; Cho BS; Kim SY; Kim YJ; Lee DG; Choi SM; Cho SG; Kim DW; Lee JW; Shin WS; Kim CC
Eur J Haematol; 2007 Nov; 79(5):398-404. PubMed ID: 17916082
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome.
Daver N; Kantarjian H; Ravandi F; Estey E; Wang X; Garcia-Manero G; Jabbour E; Konopleva M; O'Brien S; Verstovsek S; Kadia T; Dinardo C; Pierce S; Huang X; Pemmaraju N; Diaz-Pines-Mateo M; Cortes J; Borthakur G
Leukemia; 2016 Feb; 30(2):268-73. PubMed ID: 26365212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
